Summit Therapeu ADR (SMMT) Stock Price, Quote & News

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology

Sector: Healthcare

Phone: 305-203-2034

Website: www.smmttx.com

Address:

601 Brickell Key Drive, Suite 1000, Miami, United States

FE123 Jul. 17 at 5:48 PM

$IOVA Bob Duggan at $SMMT likes to say Give me 10X $IOVA

0 · Reply

JJgoodtrader Jul. 17 at 4:34 PM

$SMMT

0 · Reply

TruthBroker2 Jul. 17 at 4:29 PM

$SMMT

0 · Reply

LittleLittleRock Jul. 17 at 3:16 PM

$SMMT calls capitulating to MMs. meed news or this ride is going back to $24

1 · Reply

Boom1166 Jul. 17 at 2:59 PM

$SMMT

0 · Reply

LittleLittleRock Jul. 17 at 2:51 PM

$SMMT sideways end of week it looks like.

0 · Reply

TruthBroker2 Jul. 17 at 2:12 PM

$SMMT 30

0 · Reply

Gasmonkey124 Jul. 17 at 2:07 PM

$SMMT Don't let them cover so cheaply

0 · Reply

FE123 Jul. 17 at 2:00 PM

$SMMT 2O Billlion To Go for $IOVA

0 · Reply

ZacksResearch Jul. 17 at 1:31 PM

$SMMT is now up 58% YTD — and the story’s gaining traction 🔥 💊 Ph3 win in NSCLC with ivonescimab — a VEGF/PD-1 approach now validated by big pharma (Merck, Pfizer, BMY) 🤝 Tied up with Pfizer & Revolution Medicines on next-gen combo trials 👀 Licensing chatter with AstraZeneca still in the rumor mill Wall Street’s take on what’s next for $SMMT 👇 https://www.zacks.com/stock/research/SMMT/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-2259&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_2259

0 · Reply

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 13 days ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 17 days ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 6, 2025, 4:44 PM EDT - 5 weeks ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 8:00 AM EDT - 6 weeks ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 6 weeks ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 9:10 AM EDT - 6 weeks ago

Is SMMT Stock A Buy After Its Recent Plunge?

May 30, 2025, 2:50 PM EDT - 6 weeks ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 9:27 AM EDT - 6 weeks ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:01 AM EDT - 6 weeks ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 6:00 AM EDT - 6 weeks ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 2, 2025, 1:06 AM EDT - 2 months ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:20 PM EDT - 2 months ago

Final Trade: NVS, XLU and SMMT

NVS XLU

May 1, 2025, 4:09 PM EDT - 2 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Apr 28, 2025, 1:00 PM EDT - 2 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 25, 2025, 3:14 PM EDT - 2 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 2:50 PM EDT - 2 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 24, 2025, 4:15 PM EDT - 2 months ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 23, 2025, 3:47 PM EDT - 3 months ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 6:15 AM EDT - 3 months ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 14, 2025, 9:08 AM EDT - 3 months ago

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Mar 24, 2025, 2:17 PM EDT - 4 months ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 17, 2025, 4:24 PM EDT - 4 months ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Feb 24, 2025, 8:13 PM EST - 5 months ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Feb 24, 2025, 3:33 PM EST - 5 months ago

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24, 2025, 12:15 PM EST - 5 months ago

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 AM EST - 5 months ago

Pfizer: What The Summit Therapeutics Deal Brings

PFE

Feb 24, 2025, 6:05 AM EST - 5 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:00 AM EST - 5 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Feb 18, 2025, 9:00 AM EST - 5 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Jan 18, 2025, 9:33 AM EST - 6 months ago

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 13, 2025, 6:10 PM EST - 6 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 7, 2025, 7:00 AM EST - 6 months ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 11:46 PM EST - 6 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD JANX LUNR

Dec 2, 2024, 2:10 PM EST - 8 months ago

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Nov 26, 2024, 4:15 PM EST - 8 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2024, 2:14 PM EST - 9 months ago

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Oct 30, 2024, 1:27 PM EDT - 9 months ago

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 9 months ago

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Oct 23, 2024, 4:15 PM EDT - 9 months ago

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Oct 4, 2024, 10:35 AM EDT - 10 months ago

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track

Oct 3, 2024, 4:15 PM EDT - 10 months ago

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Sep 19, 2024, 2:33 PM EDT - 10 months ago

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

MRK

Sep 16, 2024, 6:30 AM EDT - 10 months ago

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Sep 13, 2024, 6:52 PM EDT - 10 months ago

Trade It or Fade It: The week's big biotech moves

BNTX MRK

Sep 12, 2024, 6:30 AM EDT - 11 months ago

Summit Therapeutics Raises $235 Million

FE123 Jul. 17 at 5:48 PM

$IOVA Bob Duggan at $SMMT likes to say Give me 10X $IOVA

0 · Reply

JJgoodtrader Jul. 17 at 4:34 PM

$SMMT

0 · Reply

TruthBroker2 Jul. 17 at 4:29 PM

$SMMT

0 · Reply

LittleLittleRock Jul. 17 at 3:16 PM

$SMMT calls capitulating to MMs. meed news or this ride is going back to $24

1 · Reply

Boom1166 Jul. 17 at 2:59 PM

$SMMT

0 · Reply

LittleLittleRock Jul. 17 at 2:51 PM

$SMMT sideways end of week it looks like.

0 · Reply

TruthBroker2 Jul. 17 at 2:12 PM

$SMMT 30

0 · Reply

Gasmonkey124 Jul. 17 at 2:07 PM

$SMMT Don't let them cover so cheaply

0 · Reply

FE123 Jul. 17 at 2:00 PM

$SMMT 2O Billlion To Go for $IOVA

0 · Reply

ZacksResearch Jul. 17 at 1:31 PM

0 · Reply

TruthBroker2 Jul. 17 at 1:30 PM

$SMMT

0 · Reply

TruthBroker2 Jul. 17 at 12:52 PM

$SMMT

0 · Reply

ChillPill1972 Jul. 17 at 11:45 AM

$SMMT should have bought some Akeso a month ago… Next few days are primed for some news, hopefully Monday premarket or late Sunday.

1 · Reply

Reanimated666 Jul. 17 at 11:41 AM

$SMMT When do we hit 36?

0 · Reply

G101SPM Jul. 17 at 11:34 AM

$SMMT $28.59 bid. *DAC (dollar average cost includes SELLS at profit to reduce net cost to zero). EXIT $40.00. UPDATE: Summit Therapeutics in partnership talks with AstraZeneca (AZN) for $15 bln carries SPM 91.97 tag to confirm conclusion within reasonable range. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.

0 · Reply

ABH94 Jul. 17 at 9:53 AM

$SMMT should break 30$ today

0 · Reply

FE123 Jul. 17 at 9:15 AM

$SMMT Baker Bros have a larger percentage in $REPL Approval could come Tomorrow Night!!

0 · Reply

FE123 Jul. 17 at 8:54 AM

$SMMT 21 Billion Market Cap! $REPL $IOVA 20 Billion to Go!!

0 · Reply

TruthBroker2 Jul. 17 at 2:58 AM

$SMMT

0 · Reply

ChillPill1972 Jul. 17 at 1:41 AM

$SMMT Akeso Announces First Patient Enrolled in the Phase III Trial AK112-312/HARMONi-GI6 of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer HONG KONG, July 15, 2025 - Akeso, Inc. is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC).

0 · Reply

TruthBroker2 Jul. 17 at 1:23 AM

$SMMT All time High

0 · Reply

Reneejordan001 Jul. 17 at 12:26 AM

$SMMT This company can be the next Merck if the their clinical trials pan out. 🤞

0 · Reply

Market Cap	18.09B
Revenue (ttm)	0.00
Net Income (ttm)	-221.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,986,063
Avg Vol	4,222,564
Day's Range	N/A - N/A
Shares Out	742.67M
Stochastic %K	96%
Beta	-1.01
Analysts	Strong Sell
Price Target	$34.10